Literature DB >> 6302639

Iron in neoplastic disease.

E D Weinberg.   

Abstract

Normal and neoplastic cells have similar needs for iron, but the latter may exhibit altered mechanisms of iron acquisition that permit continued multiplication in host iron-restricted tissues. For example, neoplastic cells may form low molecular weight siderophores as well as increase the number of transferrin binding glycoproteins on their cell surfaces. The hosts attempt to withhold iron from neoplastic cells by preventing the return of the metal to plasma and diverting it to storage, by increasing the synthesis of ferritin to accommodate the added stores, and by surrounding tumor cells with macrophages that can ingest lactoferrin-bound iron, but these mechanisms are often not effective against the iron-accumulating mechanisms of the tumor. Persons or animals with iron overload (via ingestion, inhalation, injection, or pathophysiologic process) tend to be at greater risk than normal hosts in the development of neoplasms. The tumors are often associated with the site(s) of deposition of the metal. In addition to its neoplastic cell nutrient function, excess iron might suppress tumorcidal action of macrophages and interfere with lymphocyte traffic. Severe iron deficiency can interfere with the ability of the host to detoxify potential carcinogens as well as with its ability to activate antitumor lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6302639     DOI: 10.1080/01635588209513761

Source DB:  PubMed          Journal:  Nutr Cancer        ISSN: 0163-5581            Impact factor:   2.900


  10 in total

1.  T-cell mitogenesis stimulates the synthesis of a mRNA species coding for a 43-kDa peptide reactive with CM-H-9, a monoclonal antibody specific for placental isoferritin.

Authors:  C Moroz; N Shterman; B Kupfer; I Ginzburg
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

2.  In vitro antiproliferative activity of 2'-(2-hydroxyphenyl)-2'-thiazoline-4'-carboxylic acid and its methyl ester on L1210 and P388 murine neoplasms.

Authors:  G T Elliot; K F Kelly; R L Bonna; T R Wardlaw; E R Burns
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Structure and expression of ferritin genes in a human promyelocytic cell line that differentiates in vitro.

Authors:  C C Chou; R A Gatti; M L Fuller; P Concannon; A Wong; S Chada; R C Davis; W A Salser
Journal:  Mol Cell Biol       Date:  1986-02       Impact factor: 4.272

4.  Hepatic iron contents and response to interferon-alpha in patients with chronic hepatitis C. Relationship to genotypes of hepatitis C virus.

Authors:  N Izumi; N Enomoto; M Uchihara; T Murakami; K Ono; O Noguchi; S Miyake; T Nouchi; K Fujisawa; F Marumo; C Sato
Journal:  Dig Dis Sci       Date:  1996-05       Impact factor: 3.199

Review 5.  Iron, microbiota and colorectal cancer.

Authors:  Oliver Ng
Journal:  Wien Med Wochenschr       Date:  2016-08-30

6.  Inflammation triggers hypoferremia and de novo synthesis of serum transferrin and ceruloplasmin in mice.

Authors:  D L Beaumier; M A Caldwell; B E Holbein
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

7.  Effects of cellular iron deficiency on the formation of vascular endothelial growth factor and angiogenesis. Iron deficiency and angiogenesis.

Authors:  Jonathan Eckard; Jisen Dai; Jing Wu; Jinlong Jian; Qing Yang; Haobin Chen; Max Costa; Krystyna Frenkel; Xi Huang
Journal:  Cancer Cell Int       Date:  2010-08-19       Impact factor: 5.722

8.  Expression of E-cadherin and other paracellular junction genes is decreased in iron-loaded hepatocytes.

Authors:  John P Bilello; Edward E Cable; Harriet C Isom
Journal:  Am J Pathol       Date:  2003-04       Impact factor: 4.307

Review 9.  Iron, radiation, and cancer.

Authors:  R G Stevens; D R Kalkwarf
Journal:  Environ Health Perspect       Date:  1990-07       Impact factor: 9.031

10.  Interactions between microenvironment and cancer cells in two animal models of bone metastasis.

Authors:  S Blouin; M F Baslé; D Chappard
Journal:  Br J Cancer       Date:  2008-02-05       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.